PMID- 36520215
OWN - NLM
STAT- MEDLINE
DCOM- 20231023
LR  - 20231023
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 149
IP  - 9
DP  - 2023 Aug
TI  - The role of systemic inflammatory response index (SIRI) and tumor-infiltrating 
      lymphocytes (TILs) in the prognosis of patients with laryngeal squamous cell 
      carcinoma.
PG  - 5627-5636
LID - 10.1007/s00432-022-04469-1 [doi]
AB  - OBJECTIVE: Systemic inflammatory response index (SIRI) values and 
      tumor-infiltrating lymphocytes (TILs) are associated with the prognosis of 
      various tumors. There is minimal evidence of those two as prognostic markers in 
      laryngeal squamous cell carcinoma (LSCC). In this study, we aimed to examine the 
      predictive value of SIRI and tumor-infiltrating CD3(+)/CD4(+)/CD8(+) T cells in 
      the prognosis of patients who underwent partial or total laryngectomy. STUDY 
      DESIGN: A total of 78 patients with LSCC who underwent total or partial 
      laryngectomy at the Eye, Ear, Nose, and Throat Hospital of Fudan University 
      between 2013 and 2015 were retrospectively analyzed. METHODS: The tumor tissues 
      of 78 LSCC patients were retrospectively evaluated using immunohistochemical 
      staining for CD3+ /CD4+ /CD8+ -cells. The overall survival (OS) and disease-free 
      survival (DFS) rates were recorded using the Kaplan-Meier method. RESULTS: 
      Patients with high immunoscore (IS) (3-4) had prolonged survival (P < 0.001 for 
      OS). High SIRI values were independently associated with poorer OS and DFS 
      (P = 0.018 for OS; P = 0.016 for DFS). CD8(+) TILs and SIRI values showed a- 
      negative association (P < 0.01). Patients with low SIRI values and high IS had 
      better 5-year OS and DFS than those with high SIRI values and low IS (P < 0.001 
      for OS; P = 0.0014 for DFS). Patients with 'hot' tumor had a higher 5-year OS 
      than those with 'excluded' or 'cold' phenotype. CONCLUSIONS: The SIRI values and 
      the density of TILs may help predict LSCC patients' outcomes after surgery. The 
      combination of SIRI and IS may be a new component of the tumor, nodes, and 
      metastases (TNM) classification of cancer and prognostic factor for T-cell-target 
      immunotherapy.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Wang, Tian
AU  - Wang T
AD  - Department of Otolaryngology-HNS, Eye, Ear, Nose and Throat Hospital, Shanghai 
      Key Clinical Disciplines of Otorhinolaryngology, Fudan University School of 
      Medicine, 83 Fenyang Road, Shanghai, 200031, People's Republic of China.
FAU - Zhang, Duo
AU  - Zhang D
AD  - Department of Otolaryngology-HNS, Eye, Ear, Nose and Throat Hospital, Shanghai 
      Key Clinical Disciplines of Otorhinolaryngology, Fudan University School of 
      Medicine, 83 Fenyang Road, Shanghai, 200031, People's Republic of China.
FAU - Tang, Di
AU  - Tang D
AD  - Department of Otolaryngology-HNS, Eye, Ear, Nose and Throat Hospital, Shanghai 
      Key Clinical Disciplines of Otorhinolaryngology, Fudan University School of 
      Medicine, 83 Fenyang Road, Shanghai, 200031, People's Republic of China.
FAU - Heng, Yu
AU  - Heng Y
AD  - Department of Otolaryngology-HNS, Eye, Ear, Nose and Throat Hospital, Shanghai 
      Key Clinical Disciplines of Otorhinolaryngology, Fudan University School of 
      Medicine, 83 Fenyang Road, Shanghai, 200031, People's Republic of China.
FAU - Lu, Li-Ming
AU  - Lu LM
AD  - Shanghai Institute of Immunology, Shanghai Jiaotong University School of 
      Medicine, 280 South Chongqing Road, Shanghai, 200025, People's Republic of China. 
      lulunew2003@163.com.
FAU - Tao, Lei
AU  - Tao L
AD  - Department of Otolaryngology-HNS, Eye, Ear, Nose and Throat Hospital, Shanghai 
      Key Clinical Disciplines of Otorhinolaryngology, Fudan University School of 
      Medicine, 83 Fenyang Road, Shanghai, 200031, People's Republic of China. 
      doctortaolei@163.com.
LA  - eng
GR  - (82103316, 81772878, 30972691）/the National Natural Science Foundation of China/
GR  - No. SHDC2020CR6011/This study was supported by Clinical Research Plan of SHDC/
GR  - 16411950100/the Science and Technology Commission of Shanghai Municipality under 
      Grand/
GR  - 11JC1410802/the Shanghai Municipal Science and Technology Foundation under Grand/
PT  - Journal Article
DEP - 20221215
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
SB  - IM
MH  - Humans
MH  - *Lymphocytes, Tumor-Infiltrating
MH  - CD8-Positive T-Lymphocytes
MH  - Squamous Cell Carcinoma of Head and Neck/surgery
MH  - Retrospective Studies
MH  - Prognosis
MH  - *Head and Neck Neoplasms
MH  - Systemic Inflammatory Response Syndrome
OTO - NOTNLM
OT  - CD3
OT  - CD8
OT  - IS
OT  - Laryngeal squamous cell carcinoma (LSCC)
OT  - SIRI
OT  - Tumor-infiltrating lymphocytes (TILs)
EDAT- 2022/12/16 06:00
MHDA- 2023/10/23 00:45
CRDT- 2022/12/15 11:15
PHST- 2022/08/30 00:00 [received]
PHST- 2022/11/06 00:00 [accepted]
PHST- 2023/10/23 00:45 [medline]
PHST- 2022/12/16 06:00 [pubmed]
PHST- 2022/12/15 11:15 [entrez]
AID - 10.1007/s00432-022-04469-1 [pii]
AID - 10.1007/s00432-022-04469-1 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2023 Aug;149(9):5627-5636. doi: 
      10.1007/s00432-022-04469-1. Epub 2022 Dec 15.